People
Daniel M. Skovronsky, MD, PhD
Chief Scientific and Product Office and President, Lilly Research Laboratories
Eli Lilly and Company
Biography
Daniel M. Skovronsky, M.D., Ph.D., is chief scientific and product officer of Eli Lilly and Company, and president of Lilly Research Laboratories. In this combined role, Dan heads research and development at Lilly while also carrying global responsibility for commercial products across Lilly Cardiometabolic Health, Lilly Immunology, and Lilly Neuroscience. The span of this role reflects Lilly’s commitment to the full spectrum of medicine development, from initial discovery through successful commercialization, recognizing that innovation isn’t finished when a molecule becomes a medicine, it’s only finished when patients use that medicine to improve their health.
Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, he has held various roles with increasing responsibility and leadership. Dan also oversees Lilly’s External Innovation Team, including Catalyze360, which empowers biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities.
Dan completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received both his M.D. and Ph.D. from the University of Pennsylvania and earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University.
He has received numerous awards and recognitions, including Time Magazine 100 Most Influential people in health, Honorary Doctorate of Medicine from Oakland University, and the Melvin R. Goodes Prize by the Alzheimer’s Drug Discovery Foundation for his lifetime efforts against Alzheimer’s disease. Dan was also recently named as the 2025 Kavli Oxford Lecture Award recipient by the University of Oxford (United Kingdom) for contributions of incretins to human health. Medicines he has helped create have been widely recognized including the Cleveland Clinic #1 Innovation of 2011 (for amyloid imaging), the 2021 Roy VagelosPro Bono Humanum Award (for COVID19 antibody) and the Galien Foundation 2023 Best Pharmaceutical Product Prix Galien (for tirzepatide).
Follow Dan on LinkedIn to see his latest updates